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Mung bean seed coat (MBSC) is a healthcare product in Asian countries. The aim of this study was to 
investigate the effect of an MBSC ethanol extract on the bioavailability of cyclosporine A (CsA) in rats. 
Rats were orally dosed with CsA alone or in combination with MBSC ethanol extracts (500 mg/kg, 
p.o.). The blood levels of CsA were assayed by liquid chromatography with an electrospray ionization 
source and tandem mass spectrometry (LC-MS/MS). The everted rat intestinal sac technique was used 
to determine the influence of MBSC on the absorption of CsA. The results reveal that combined CsA 
intake with MBSC decreased the Cmax, AUC0-t, t1/2z and MRT0-t values of CsA by 24.96%, 47.28%, 34.73% 
and 23.58%, respectively (P<0.05), and significantly raised the CL/F by 51.97% (P<0.01). The in vitro 
results demonstrated that significantly less CsA was absorbed (P<0.05). The overall results indicate that 
after being concomitantly ingested, MBSC reduced the bioavailability of CsA, at least partially, in the 
absorption phase.
Uniterms: Mung bean/seed coat/health care use. Mung bean/seed coat/ethanolic extract/properties. 
Cyclosporine A/bioavailability.
O tegumento da semente de feijão-mungo (MBSC) é um produto para tratamento de saúde em 
países asiáticos. O objetivo deste estudo foi investigar o efeito de extrato etanólico de MBSC na 
biodisponibilidade da ciclosporina A (CVsA) em ratos. Administrou-se aos ratos CsA sozinha ou em 
associação com extrato etanólico de MBSC (500 mg/kg, p.o.), por via oral. Os níveis sanguíneos de 
CSA foram determinados por cromatografia a líquido com ionização por electrospray, associada à 
espectrometria de massas (LC-MS/MS). Utilizou-se a técnica de inversão do saco intestinal de rato para 
determinar a influência do MBSC na absorção de CsA. Os resultados revelaram que a ingestão combinada 
de CsA e MBSC diminuiu os valores de Cmax, AUC0-t, t1/2z e MRT0-t de CsA em 24%, 47,28%, 34,73% 
e 23,58%, respectivamente (P<0.05), e aumentou, significativamente, CL/F em 51,79% (P<0.05). Os 
resultados in vitro demostraram que, significativamente, menos CsA foi absorvida (P<0.05). Os resultados 
totais indicaram que após ser concomitantemente ingerida, a MBSC reduziu, ao menos parcialmente, a 
biodisponibilidade de CsA, na fase de absorção. 
Unitermos: Feijão-mungo/tegumento da semente/uso para a saúde. Feijão-mungo/tegumento da semente/
extrato etanólico/propriedades. Ciclosporina A/biodisponibilidade.
INTRODUCTION
In daily practice, drugs are often taken simultaneously 
with foods or nutriments. However, food-drug interactions 
(FDIs), with commonly overlooked hidden risks, 
unintentionally result in therapeutic failure or increased 
toxicity of drugs, thus adversely affecting patient care, 
contributing to morbidity and prolonging treatment 
or hospitalization stay (Bushra, Slam, Khan, 2011). 
Therefore, identifying FDIs, understanding the relevant 
mechanisms, and evaluating and managing the risks 
are clinically significant before diagnosis and treatment 
protocol selection. Cyclosporine A (CsA), an important 
calcineurin inhibitor, ensures, at therapeutic concentrations, 
effective immunosuppression after transplants of a variety 
of solid organs. Sub-therapeutic CsA concentrations, 
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which are prone to inducing acute cellular rejection, lead to 
hepatotoxicity, nephrotoxicity and neurotoxicity (Kuypers, 
2008). Previously, Yang (2002) reported six patients who 
had received a renal transplantation and suffered from 
graft rejection after concomitantly drinking mung bean 
soup. The trough concentrations of CsA decreased from 
(390.00±112.21) ng/mL before mung bean food intake to 
(287.33±94.21) ng/mL (P < 0.001) after.
Mung bean (Vigna radiatae L.) seed coat (MBSC) is 
a traditional Chinese medicine targeting several diseases, 
generally by reducing fever and removing toxic substances 
(Yao et al., 2008). Mung bean is a ubiquitous food because 
the embryo is abundant in nutrients such as starch, fiber 
and protein, while most bioactive phytochemicals are 
contained in the coats (Cao et al., 2011; Khan, Jacobsen, 
Eggum, 2006). Besides, the pharmacological effects 
of MBSC, such as antitumor (Soucek et al., 2006), 
antidiabetic (Peng et al., 2008), anti-inflammatory 
(Prabhakar et al., 1981), antimicrobial (Randhir, Lin, 
Shetty, 2004) and antioxidant (Soucek et al., 2006), have 
also been spotlighted. Hence, the present study mostly 
focused on the bioactivity of MBSC.
The purpose of this study was to verify the 
pharmacokinetic effects of mung bean seed coat (MBSC) 
on CsA. We designed a parallel experiment by pretreating 
rats with MBSC ethanol extract or vehicle solution for 
7 consecutive days before the administration of CsA 
to investigate the resultant food-drug pharmacokinetic 
interaction. Furthermore, whether intestinal absorption 
was functionally modulated by MBSC was tested by 
everted gut sac studies.
MATERIAL AND METHODS
Chemicals and reagents
Dried MBSC was purchased from Hui-Rui 
Chinese Medicine Science Co., Ltd. (Bozhou, China). 
CsA (purity>99%) and tacrolimus (Internal standard, 
purity>99%) were obtained from the China Pharmacy 
Biological Products Examination Institute (Beijing, 
China). CsA was donated by Zhongmei Huadong 
Pharmaceutical Co., Ltd. (Hangzhou, China). HPLC-grade 
methanol and acetonitrile were obtained from the Fisher 
Scientific Company (Emerson, USA). Other chemicals 
and reagents were all analytically pure (Jinfeng Chemical 
Factory, Tianjin, China).
Experimental animals
Male Sprague-Dawley rats, aged 8-9 weeks old, 
were purchased from the Experimental Animal Center of 
Tongji Medical College (Huazhong University of Science 
and Technology, China). The experimental rats were 
maintained at the Experimental Animal Center of Tongji 
Medical College under specific pathogen-free conditions. 
The rats were housed in stainless steel cages and kept 
at a controlled temperature (25 ± 2 °C) and ambient 
humidity (50% to 75%). Light was maintained following 
a 12 h dark-light cycle. All of the rats were continuously 
provided with a chow diet and tap water throughout the 
experiment. The experiments were carried out according 
to the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals approved by the Animal 
Ethics Committee of Tongji Medical College, Huazhong 
University of Science and Technology.
Preparation of the aqueous extract of MBSC
MBSC (500 g) was pre-immersed in 50% ethanol 
aqueous solution (solid: liquid, 1:10) and then refluxed at 
80 °C for 150 min and extracted three times. The combined 
extracts were filtered through gauze, to which was then 
added appropriate amounts of diatomaceous earth. This was 
stirred at ambient temperature for 2-3 min, and then allowed 
to stand for 5 min. After the removal of macromolecular 
compounds by adsorption, the solution was distilled under 
reduced pressure, and the combined dry residue was 
extracted with petroleum ether (500 mL) to remove lipid-
soluble constituents. The aqueous phase was then collected, 
freeze-dried as the aqueous extract of MBSC and stored.
Overall pharmacokinetics study
Twelve rats (8-9 weeks old) were randomly divided 
into two groups, which were administered cyclosporine 
A (CsA) alone or in combination with MBSC extract 
respectively. Once daily for six consecutive days, the rats 
in the combined administration group were orally given 
500 mg/kg MBSC extract (dissolved in 0.5% CMC-Na), 
and those in the CsA group were orally administered with 
equal volumes of 0.5% CMC-Na solution. All rats had free 
access to food and water. On the seventh day, the rats were 
treated with vehicle or MBSC extract. The rats were fasted 
for no less than 12 h before intragastric administration, but 
retained free access to water. Meanwhile, the two groups 
were orally given 10 mg/kg CsA (dissolved in olive oil) 
after 30 min of the above administration procedure. Blood 
(0.3 mL) was collected from the carotid artery at 0, 0.83, 
1.5, 3, 5, 6, 8, 12, 24 and 36 h after administration. Whole 
blood was stored at -80 °C. After the experiment, the rats 
were sacrificed by cervical dislocation under anesthesia.
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Everted intestinal sac study
Twelve rats (8-9 weeks old) were randomly divided 
into a control group and an MBSC extract pretreatment 
group, in which the rats were orally administered with 0.5% 
CMC-Na solution and MBSC extract solution (dissolved in 
0.5% CMC-Na) respectively once a day for six continuous 
days. On the seventh day, the rats were fasted for no less 
than 12 h before experiment with free water access. Thirty 
minutes after the corresponding pretreatment, the rats were 
fixed after ether anesthesia. Everted sacs were prepared 
by slightly modifying a procedure described previously 
(Sakamoto et al., 2006). The abdomens were incised open 
along the abdominal midline to carefully peel the intestinal 
canal off the mesentery. Then, 10 cm of the duodenum, 
jejunum, ileum and colon were disconnected, put into 
37 °C K-R buffer (133 mM NaCl, 4.75 mM KCl, 3.33 mM 
CaCl2, 2.67 mM NaH2PO4, 0.02 mM MgCl2, 16.31 mM 
NaHCO3, and 8.75 mM C6H12O6, pH 7.0-7.2) and washed 
until the exhaustion of intestinal contents, after which the 
mesentery and fat on the surface of intestinal segments 
were cautiously removed. The rats were sacrificed by 
cervical dislocation under anesthesia. After being ligated 
onto a self-prepared plastic sleeve with one end, the 
intestinal canal was carefully everted and rinsed with 
K-R buffer, and then the other end was also ligated into 
a capsular shape. Blank K-R buffer (1 mL) was added to 
the intestinal sac, which was then put into a water bath 
already containing K-R buffer, magnetically stirred at 
37 °C under a 95% O2/5% CO2 atmosphere. After 5 min 
of equilibrium, the original K-R buffer was removed from 
the water bath, into which was then added 250 mL of K-R 
liquid containing 5 μg/mL CsA. The solution (200 μL) 
in the intestinal sac was sampled after 15, 30, 45, 60, 75 
and 90 min of incubation, and same volume of blank K-R 
buffer was added simultaneously. The absorptive solution 
was stored at -80 °C until analysis.
Lactate dehydrogenase (LDH) release of everted 
gut sacs
LDH is an intracellular enzyme, detected following 
damage to cell membranes, and has been used as a 
biochemical marker of intestinal wall damage (Brown 
et al., 2002; Swenson, Milisen, Curatolo, 1994). The 
feature was determined by means of LDH release tests, 
as previously reported (Rong et al., 2013).
Analytical methods
All analyses were conducted on a Shimadzu LC 
system equipped with two LC-20AD pumps, an SIL-
20ACHT autosampler, an SCL-10Avp control system, a 
DGU-20A3 on-line degasser and a CTO-20AC column 
oven (Chiyoda-Ku, Japan). Separation was performed 
on a Dimonsil C18 column (150 mm × 2.1 mm i.d., 5 mm, 
Dikma, China) equipped with a Phenomenex guard 
column (5.0 mm × 2.0 mm i.d., Phonomenon, Guangzhou, 
China). The mobile phase consisted of methanol and 0.1% 
formic acid (10:90, v/v). The temperature was maintained 
at 65 oC for the column and 15 oC for the autosampler. 
The flow rate was 0.3 mL/min. Mass spectrometric 
analyses were conducted on an API 3,200 LC–MS-MS 
system (Applied Biosystems, Foster City, USA) equipped 
with an electrospray ionization source (ESI) in triple-
quadrupole mode. The curtain gas and collision activated 
dissociation were 20 and 5 psi, respectively. The other 
working parameters were set as follows: spray voltage, 
5,000 V; source temperature, 450 oC; GAS1, 60 psi 
and GAS2, 45 psi. The declustering potential, entrance 
potential, collision energy and collision cell exit potential 
were optimized, respectively, as 77, 14, 20 and 22 V for 
CsA; these values were 112, 34 and 70 and 8.0 V for 
sirolimus (IS). LC–ESI-MS-MS was performed in positive 
ionization mode with multiple reaction monitoring (MRM) 
of the transitions m/z ([M+Na]+) 1225.8→m/z 1225.8 
for CsA and ([M+NH4]+) m/z 821.9→m/z 409.4 for 
tacrolimus. Data acquisition and analysis were controlled 
using Analyst 1.5 software (Applied Biosystems).
Sample preparation
In this study, all samples were detected by liquid 
chromatography–electrospray ionization tandem mass 
spectrometry (LC-ESI-MS/MS). Rat whole blood 
(200 μL) or the absorptive solution from the gut sac was 
placed in a 10 mL glass centrifuge tube, to which was 
then added 50 μL of 5 M NH4AC to break the cells. The 
resultant solution was mixed for 1 min and allowed to stand 
for 10 min, to which was then added 20 μL of tacrolimus 
solution (1.012 μg/mL). This was the mixed, extracted 
with 3 mL of ether for 5 min, and centrifuged at 3,500 rpm 
for 5 min. The upper organic layer was collected and dried 
under a nitrogen stream at 40 °C. The dried residue was 
redissolved in 100 μL of the mobile phase, transferred to 
an EP tube, and centrifuged at 12,000 rpm for 5 min, from 
which 10 μL of the supernatant was collected for analysis.
Data transformation
The plasma concentration-time data were analyzed 
using the non-compartmental model in DAS2.0 to obtain 
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the main pharmacokinetic parameters (Li et al., 2013; 
Zhang et al., 2012). Peak concentration (Cmax) and time-
to-peak (tmax) were measured, area under the plasma 
concentration-time curve (AUC) was calculated by the 
trapezoidal rule, and the half-life of elimination (t1/2) was 
calculated by 0.693/ke (ke refers to the terminal elimination 
rate constant derived from the slope of terminal straight 
line of logarithmic plasma concentration-time curve). The 
apparent clearance rate of oral administration (CL/F) was 
calculated by dose/AUC0-t. All the other parameters were 
calculated based on the non-compartmental model, and 
the mean residence time (MRT) of drug molecules was 
calculated as 1.44t1/2.
The rate of drug transport was usually expressed 
as the apparent permeability coefficient (Papp). It was 
calculated from the following equation:
Papp=(dQ/dt)/(C0×A)
where dQ/dt is the steady-state appearance rate on the 
acceptor solution, A is the surface area of the intestinal sac 
and C0 is the initial concentration inside the sac.
STATISTICAL ANALYSIS
The experimental data were expressed as mean ± SD 
or mean, and were analyzed by SPSS 16.0 (Li, et al., 2013; 
Zhang et al., 2012). The main parameters of each group 
were subjected to one-way analysis variance (ANOVA) 
and Student’s t-test, with P<0.05 being statistically 
significantly different.
RESULTS AND DISCUSSION
Method validation
Briefly, the seven-point calibration curve for CsA (0, 
50, 100, 200, 400, 600 and 1200 ng/mL) was constructed 
by plotting the peak area ratio of CsA-IS against the real 
concentration of the calibration standards in rat plasma 
and K-R buffer. Inter-day and intra-day repeatability 
were assessed with QC samples (50, 200 and 1000 ng/mL 
of CsA in rat whole blood or absorptive solution of gut 
sac). The accuracy and precision were defined by the 
percentage of relative standard deviation (RSD) of five 
standards at five different concentrations analyzed on 
the same day. Stability was expressed by the relative 
error between the initial and tested concentration of QC 
samples under different sample preparatory conditions, 
such as short-term, long-term, freeze-thaw cycle and post-
preparation stability. The results indicate that the lower 
limit of quantification was 50 ng/mL with a precision 
(RSD) less than 9.01% and a accuracy ranging from 94.5% 
to 107.76%. The recovery of CsA was no less than 87.3% 
with a coefficient of variation less than 3.2%. Short-term, 
long-term and three freeze-thaw stability studies indicated 
that analytes were stable under the above conditions. Ion 
suppression and enhancement from plasma and K-R buffer 
matrix were negligible under the present conditions.
LDH release in the everted gut sac model
The results reveal that there were no significant 
differences in LDH activity at 30, 60, 90 and 120 min, 
while a significant difference was found at 180 min, 
suggesting that the everted gut sacs began to lose viability 
after 120 min. It was concluded that the everted gut sacs 
maintained their viability during the experimental period 
(90 min) and consequently this model was suitable for 
testing drug transport.
Effects of MBSC on the pharmacokinetics of CsA 
in rats
The whole blood concentration-time curves of CsA 
after oral dosing with CsA alone and in combination with 
MBSC are illustrated in Figure 1. The pharmacokinetic 
parameters of CsA are shown in Table I. Pretreating the 
rats with MBSC significantly reduced the Cmax, AUC0-t, t1/2z 
and MRT of CsA by 24.96% (P<0.05), 47.28% (P<0.01), 
34.73% (P<0.05)and 23.58% (P<0.01), respectively, and 
significantly elevated CL/F by 51.97% (P<0.01).
FIGURE 1 - Mean blood concentration-time curve of CsA after 
oral administration with or without MBSC extract (500 mg/kg, 
i.g.). Each point represents the mean±SD. (n=6).
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TABLE I - Effect of treatment with herbal extract on the pharmacokinetic parameters of CsA
Parameters CsA alone CsA+ MBSCs
AUC0-t ( ng·h/mL) 7846.32±988.49 4137.10±281.34**
t1/2z (h) 13.36±2.41 8.72±2.57*
Cmax (ng/mL) 493.87±102.69 370.60±31.48*
Tmax (h) 5.20±1.17 5.40±0.49
CL/F (L/h) 1.10±0.18 2.29±0.21**
MRT (h) 13.19±1.04 10.08±0.60**
Each point represents the mean±S.D. (n=6). * p<0.05, ** p<0.01, significantly different compared with CsA alone
FIGURE 2 - Average transport of CsA (ng) from the mucosal to serosal surface across duodenum, jejunum, ileum and colon with 
or without MBSC extract pretreatment (500 mg/kg, i.g.). Each point represents the mean±SD. (n=3).
Effects of MBSC on CsA absorption in intestinal 
gut sacs
Figure 2 shows the effects of MBSC treatment on 
the absorption of CsA in the duodenum, jejunum, ileum 
and colon. Table II shows the Papp of CsA in each intestinal 
segment in the everted gut sac study. The results demonstrate 
that the rank order of Papp of CsA in each intestinal segment 
was as follows: ileum > duodenum ≈ jejunum > colon. The 
ileum showed the greatest permeability, which is consistent 
with previously published data (Drewe, Beglinger, Kssel, 
1992; Huang et al., 2010). Pretreatment with multiple 
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doses of MBSC decreased the Papp of CsA in most intestinal 
segments, except for the duodenum. Altogether, the 
results reveal that pretreatment with 500 mg/kg MBSC 
significantly decreased the Papp of CsA in the jejunum, ileum 
and colon (P < 0.05).
In this study, combined intake of CsA with MBSC 
markedly decreased the AUC0-t (P<0.01), Cmax (P<0.05), 
t1/2z (P<0.05) and MRT (P<0.01) of CsA, and remarkably 
increased the CL/F (P<0.01), demonstrating significantly 
reduced bioavailability of CsA. The semi-log profiles 
(data not shown) indicate that MBSC seemed to inhibit 
the intestinal absorption and enhanced the intestinal/
liver elimination of CsA. It is acknowledged that 
combined intake of CsA with foods and beverages can 
affect the rate and extent of drug absorption (Chiang et 
al., 2006), probably by impacting intestinal physiological 
factors and transport (Boullata, Hudson, 2012). Our 
everted gut sac study indicates that MBSC significantly 
decreased the accumulative absorption of CsA in 
each intestinal segment, suggesting that reduced CsA 
bioavailability occurs, at least partially, at the absorption 
site. Given that accelerated transit of a drug through 
the gastrointestinal tract reduces its absorption, MBSC 
might shorten drug transit time like ginger does (Platel, 
Srinivasan, 2001). In the meantime, CsA is metabolized 
in the intestine/liver by CYP3A4, and the parent drug 
is subjected to efflux by P-gp in the intestinal apical 
membrane (Pal, Mitra, 2006). Dürr reported that St John’s 
wort lowers the blood concentration of CsA by inducing 
CYP3A4 and intestinal P-gp in humans (Dürr et al., 2000). 
In addition, Yang reported that the ingestion of ginkgo and 
onion decreases the bioavailability of CsA via inducing 
CYP3A in rats (Yang et al., 2006). Moreover, Chiang 
also found that ginger reduces the blood concentration of 
CsA by the induction of CYP3A4 (Chiang et al., 2006). 
However, whether MBSC can accelerate the metabolism 
of CsA by inducing intestinal or liver CYP3A in rats, or 
increase the efflux of CsA by inducing intestinal P-gp 
expression or activity remain unknown. The underlying 
mechanisms should be further clarified in future.
CONCLUSIONS
The present study was conducted to verify the 
interaction between MBSC and CsA. The results of this 
study demonstrate that combined treatment with CsA and 
MBSC could significantly reduce the oral bioavailability 
of CsA, at least partially by inhibiting absorption, 
suggesting that combined use of MBSC with CsA should 
be closely monitored for potential food-drug interactions.
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